Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748189 · ClinicalTrials.gov registry record · Phase 3
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
NCT00748189 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 447 participants.
The verdict
NCT00748189, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.
Interventions
- DRUG chlorambucil, tablets
- DRUG ofatumumab (GSK1841157) infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2008-12-22 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748189
The ClinicalTrials.gov registry entry for NCT00748189 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chlorambucil, tablets is the first listed.
NCT00748189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748189 about?
NCT00748189 is a clinical study titled "Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia". The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.
What is the current status of trial NCT00748189?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2008-12-22. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT00748189?
The interventions under investigation include: chlorambucil, tablets (DRUG), ofatumumab (GSK1841157) infusion (DRUG).
Who is sponsoring clinical trial NCT00748189?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.